首页 > 最新文献

Journal of Gastric Cancer最新文献

英文 中文
Real-World Compliance of Surgical Treatment According to the Korean Gastric Cancer Guideline 2018: Evaluation From the Nationwide Survey Data 2019 in Korea. 根据2018年韩国胃癌指南的手术治疗的现实依从性:来自韩国2019年全国调查数据的评估
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-10-01 DOI: 10.5230/jgc.2023.23.e32
Sang Soo Eom, Sin Hye Park, B. Eom, Hong Man Yoon, Young-Woo Kim, K. Ryu
PURPOSEThis study evaluated real-world compliance with surgical treatment according to Korea's gastric cancer treatment guidelines.MATERIALS AND METHODSThe 2018 Korean Gastric Cancer Treatment Guidelines were evaluated using the 2019 national survey data for surgically treated gastric cancer based on postoperative pathological results in Korea. In addition, the changes in surgical treatments in 2019 were compared with those in the 2014 national survey data implemented before the publication of the guidelines in 2018. The compliance rate was evaluated according to the algorithm recommended in the 2018 Korean guidelines.RESULTSThe overall compliance rates in 2019 were 83% for gastric resection extent, 87% for lymph node dissection, 100% for surgical approach, and 83% for adjuvant chemotherapy, similar to 2014. Among patients with pathologic stages IB, II, and III disease who underwent total gastrectomy, the incidence of splenectomy was 8.08%, a practice not recommended by the guidelines. The survey findings revealed that 48.66% of the patients who underwent gastrectomy had pathological stage IV disease, which was not recommended by the 2019 guidelines. Compared to that in 2014, the rate of gastrectomy in stage IV patients was 54.53% in 2014. Compliance rates were similar across all regions of Korea, except for gastrectomy in patients with stage IV disease.CONCLUSIONSReal-world compliance with gastric cancer treatment guidelines was relatively high in Korea.
目的:本研究根据韩国胃癌治疗指南评估手术治疗的实际依从性。材料与方法利用2019年韩国胃癌手术治疗全国调查数据,以术后病理结果为基础,对2018年《韩国胃癌治疗指南》进行评价。此外,将2019年手术治疗的变化与2018年指南发布前实施的2014年全国调查数据进行了比较。遵守率是根据2018年韩国版指南中推荐的算法进行评估的。结果2019年胃切除术总体依从率为83%,淋巴结清扫87%,手术入路100%,辅助化疗83%,与2014年相似。病理分期为IB、II和III的患者行全胃切除术,脾切除术的发生率为8.08%,这是指南不推荐的做法。调查结果显示,接受胃切除术的患者中有48.66%患有病理性IV期疾病,这是2019年指南不建议的。与2014年相比,2014年IV期患者胃切除术率为54.53%。除了IV期患者的胃切除术外,韩国所有地区的依从率相似。结论韩国胃癌治疗指南的实际依从性较高。
{"title":"Real-World Compliance of Surgical Treatment According to the Korean Gastric Cancer Guideline 2018: Evaluation From the Nationwide Survey Data 2019 in Korea.","authors":"Sang Soo Eom, Sin Hye Park, B. Eom, Hong Man Yoon, Young-Woo Kim, K. Ryu","doi":"10.5230/jgc.2023.23.e32","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e32","url":null,"abstract":"PURPOSE\u0000This study evaluated real-world compliance with surgical treatment according to Korea's gastric cancer treatment guidelines.\u0000\u0000\u0000MATERIALS AND METHODS\u0000The 2018 Korean Gastric Cancer Treatment Guidelines were evaluated using the 2019 national survey data for surgically treated gastric cancer based on postoperative pathological results in Korea. In addition, the changes in surgical treatments in 2019 were compared with those in the 2014 national survey data implemented before the publication of the guidelines in 2018. The compliance rate was evaluated according to the algorithm recommended in the 2018 Korean guidelines.\u0000\u0000\u0000RESULTS\u0000The overall compliance rates in 2019 were 83% for gastric resection extent, 87% for lymph node dissection, 100% for surgical approach, and 83% for adjuvant chemotherapy, similar to 2014. Among patients with pathologic stages IB, II, and III disease who underwent total gastrectomy, the incidence of splenectomy was 8.08%, a practice not recommended by the guidelines. The survey findings revealed that 48.66% of the patients who underwent gastrectomy had pathological stage IV disease, which was not recommended by the 2019 guidelines. Compared to that in 2014, the rate of gastrectomy in stage IV patients was 54.53% in 2014. Compliance rates were similar across all regions of Korea, except for gastrectomy in patients with stage IV disease.\u0000\u0000\u0000CONCLUSIONS\u0000Real-world compliance with gastric cancer treatment guidelines was relatively high in Korea.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"29 1","pages":"535-548"},"PeriodicalIF":2.5,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90727897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Comparison of Laparoscopic and Open Gastrectomy for Patients With Gastric Cancer Treated With Neoadjuvant Chemotherapy: A Multicenter Retrospective Study Based on the Korean Gastric Cancer Association Nationwide Survey. 腹腔镜胃切除术与开放式胃切除术在胃癌新辅助化疗患者中的比较:基于韩国胃癌协会全国调查的多中心回顾性研究。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-07-01 DOI: 10.5230/jgc.2023.23.e28
Seul Ki Oh, Chang Seok Ko, Seong-A Jeong, Jeong Hwan Yook, Moon-Won Yoo, Beom Su Kim, In-Seob Lee, Chung Sik Gong, Sa-Hong Min, Na Young Kim

Purpose: Despite scientific evidence regarding laparoscopic gastrectomy (LG) for advanced gastric cancer treatment, its application in patients receiving neoadjuvant chemotherapy remains uncertain.

Materials and methods: We used the 2019 Korean Gastric Cancer Association nationwide survey database to extract data from 489 patients with primary gastric cancer who received neoadjuvant chemotherapy. After propensity score matching analysis, we compared the surgical outcomes of 97 patients who underwent LG and 97 patients who underwent open gastrectomy (OG). We investigated the risk factors for postoperative complications using multivariate analysis.

Results: The operative time was significantly shorter in the OG group. Patients in the LG group had significantly less blood loss than those in the OG group. Hospital stay and overall postoperative complications were similar between the two groups. The incidence of Clavien-Dindo grade ≥3 complications in the LG group was comparable with that in the OG group (1.03% vs. 4.12%, P=0.215). No statistically significant difference was observed in the number of harvested lymph nodes between the two groups (38.60 vs. 35.79, P=0.182). Multivariate analysis identified body mass index (odds ratio [OR], 1.824; 95% confidence interval [CI], 1.029-3.234; P=0.040) and extent of resection (OR, 3.154; 95% CI, 1.084-9.174; P=0.035) as independent risk factors for overall postoperative complications.

Conclusions: Using a large nationwide multicenter survey database, we demonstrated that LG and OG had comparable short-term outcomes in patients with gastric cancer who received neoadjuvant chemotherapy.

目的:尽管有科学证据表明腹腔镜胃切除术(LG)可用于晚期胃癌的治疗,但其在接受新辅助化疗的患者中的应用仍不确定。材料和方法:我们使用2019年韩国胃癌协会全国调查数据库,提取489例接受新辅助化疗的原发性胃癌患者的数据。经过倾向评分匹配分析,我们比较了97例LG患者和97例开放式胃切除术(OG)患者的手术结果。我们使用多变量分析调查了术后并发症的危险因素。结果:OG组手术时间明显缩短。LG组患者的失血量明显少于OG组。两组患者的住院时间和术后并发症相似。LG组Clavien-Dindo≥3级并发症发生率与OG组相当(1.03% vs. 4.12%, P=0.215)。两组淋巴结清扫数比较差异无统计学意义(38.60 vs 35.79, P=0.182)。多变量分析确定体重指数(比值比[OR], 1.824;95%置信区间[CI], 1.029-3.234;P=0.040)和切除程度(OR, 3.154;95% ci, 1.084-9.174;P=0.035)是术后并发症的独立危险因素。结论:通过一个大型的全国性多中心调查数据库,我们证明LG和OG在接受新辅助化疗的胃癌患者中具有相当的短期结果。
{"title":"Comparison of Laparoscopic and Open Gastrectomy for Patients With Gastric Cancer Treated With Neoadjuvant Chemotherapy: A Multicenter Retrospective Study Based on the Korean Gastric Cancer Association Nationwide Survey.","authors":"Seul Ki Oh,&nbsp;Chang Seok Ko,&nbsp;Seong-A Jeong,&nbsp;Jeong Hwan Yook,&nbsp;Moon-Won Yoo,&nbsp;Beom Su Kim,&nbsp;In-Seob Lee,&nbsp;Chung Sik Gong,&nbsp;Sa-Hong Min,&nbsp;Na Young Kim","doi":"10.5230/jgc.2023.23.e28","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e28","url":null,"abstract":"<p><strong>Purpose: </strong>Despite scientific evidence regarding laparoscopic gastrectomy (LG) for advanced gastric cancer treatment, its application in patients receiving neoadjuvant chemotherapy remains uncertain.</p><p><strong>Materials and methods: </strong>We used the 2019 Korean Gastric Cancer Association nationwide survey database to extract data from 489 patients with primary gastric cancer who received neoadjuvant chemotherapy. After propensity score matching analysis, we compared the surgical outcomes of 97 patients who underwent LG and 97 patients who underwent open gastrectomy (OG). We investigated the risk factors for postoperative complications using multivariate analysis.</p><p><strong>Results: </strong>The operative time was significantly shorter in the OG group. Patients in the LG group had significantly less blood loss than those in the OG group. Hospital stay and overall postoperative complications were similar between the two groups. The incidence of Clavien-Dindo grade ≥3 complications in the LG group was comparable with that in the OG group (1.03% vs. 4.12%, P=0.215). No statistically significant difference was observed in the number of harvested lymph nodes between the two groups (38.60 vs. 35.79, P=0.182). Multivariate analysis identified body mass index (odds ratio [OR], 1.824; 95% confidence interval [CI], 1.029-3.234; P=0.040) and extent of resection (OR, 3.154; 95% CI, 1.084-9.174; P=0.035) as independent risk factors for overall postoperative complications.</p><p><strong>Conclusions: </strong>Using a large nationwide multicenter survey database, we demonstrated that LG and OG had comparable short-term outcomes in patients with gastric cancer who received neoadjuvant chemotherapy.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 3","pages":"499-508"},"PeriodicalIF":2.5,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/91/f7/jgc-23-499.PMC10412975.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9980540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complication After Gastrectomy for Gastric Cancer According to Hospital Volume: Based on Korean Gastric Cancer Association-Led Nationwide Survey Data. 基于韩国胃癌协会主导的全国调查数据,根据医院容量分析胃癌切除术后并发症。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-07-01 DOI: 10.5230/jgc.2023.23.e24
Sang-Ho Jeong, Moon-Won Yoo, Miyeong Park, Kyung Won Seo, Jae-Seok Min

Purpose: This study aimed to analyze the incidence and risk factors of complications following gastric cancer surgery in Korea and to compare the correlation between hospital complications based on the annual number of gastrectomies performed.

Materials and methods: A retrospective analysis was conducted using data from 12,244 patients from 64 Korean institutions. Complications were classified using the Clavien-Dindo classification (CDC). Univariate and multivariate analyses were performed to identify the risk factors for severe complications.

Results: Postoperative complications occurred in 14% of the patients, severe complications (CDC IIIa or higher) in 4.9%, and postoperative death in 0.2%. The study found that age, stage, American Society of Anesthesiologists (ASA) score, Eastern Cooperative Oncology Group (ECOG) score, hospital stay, approach methods, and extent of gastric resection showed statistically significant differences depending on hospital volumes (P<0.05). In the univariate analysis, patient age, comorbidity, ASA score, ECOG score, approach methods, extent of gastric resection, tumor-node-metastasis (TNM) stage, and hospital volume were significant risk factors for severe complications. However, only age, sex, ASA score, ECOG score, extent of gastric resection, and TNM stage were statistically significant in the multivariate analysis (P<0.05). Hospital volume was not a significant risk factor in the multivariate analysis (P=0.152).

Conclusions: Hospital volume was not a significant risk factor for complications after gastric cancer surgery. The differences in the frequencies of complications based on hospital volumes may be attributed to larger hospitals treating patients with younger age, lower ASA scores, better general conditions, and earlier TNM stages.

目的:本研究旨在分析韩国胃癌手术后并发症的发生率和危险因素,并根据每年胃切除术次数比较医院并发症的相关性。材料和方法:回顾性分析了来自韩国64家机构的12244名患者的数据。并发症采用Clavien-Dindo分类(CDC)进行分类。进行单因素和多因素分析,以确定严重并发症的危险因素。结果:术后并发症发生率14%,严重并发症(CDC IIIa及以上)发生率4.9%,术后死亡发生率0.2%。研究发现,年龄、分期、美国麻醉医师学会(ASA)评分、东部肿瘤合作组织(ECOG)评分、住院时间、入路方式、胃切除程度随医院容量的变化差异有统计学意义(p)。结论:医院容量不是胃癌术后并发症的显著危险因素。基于医院容量的并发症频率差异可能归因于大医院治疗的患者年龄较小,ASA评分较低,一般情况较好,TNM分期较早。
{"title":"Complication After Gastrectomy for Gastric Cancer According to Hospital Volume: Based on Korean Gastric Cancer Association-Led Nationwide Survey Data.","authors":"Sang-Ho Jeong,&nbsp;Moon-Won Yoo,&nbsp;Miyeong Park,&nbsp;Kyung Won Seo,&nbsp;Jae-Seok Min","doi":"10.5230/jgc.2023.23.e24","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e24","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to analyze the incidence and risk factors of complications following gastric cancer surgery in Korea and to compare the correlation between hospital complications based on the annual number of gastrectomies performed.</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted using data from 12,244 patients from 64 Korean institutions. Complications were classified using the Clavien-Dindo classification (CDC). Univariate and multivariate analyses were performed to identify the risk factors for severe complications.</p><p><strong>Results: </strong>Postoperative complications occurred in 14% of the patients, severe complications (CDC IIIa or higher) in 4.9%, and postoperative death in 0.2%. The study found that age, stage, American Society of Anesthesiologists (ASA) score, Eastern Cooperative Oncology Group (ECOG) score, hospital stay, approach methods, and extent of gastric resection showed statistically significant differences depending on hospital volumes (P<0.05). In the univariate analysis, patient age, comorbidity, ASA score, ECOG score, approach methods, extent of gastric resection, tumor-node-metastasis (TNM) stage, and hospital volume were significant risk factors for severe complications. However, only age, sex, ASA score, ECOG score, extent of gastric resection, and TNM stage were statistically significant in the multivariate analysis (P<0.05). Hospital volume was not a significant risk factor in the multivariate analysis (P=0.152).</p><p><strong>Conclusions: </strong>Hospital volume was not a significant risk factor for complications after gastric cancer surgery. The differences in the frequencies of complications based on hospital volumes may be attributed to larger hospitals treating patients with younger age, lower ASA scores, better general conditions, and earlier TNM stages.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 3","pages":"462-475"},"PeriodicalIF":2.5,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/52/e3/jgc-23-462.PMC10412979.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10032018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of ClearCut™ Knife H-type in Endoscopic Submucosal Dissection for Gastric Neoplasms: A Multicenter, Randomized Trial. 一项多中心随机试验:ClearCut™刀h型用于胃肿瘤内镜下粘膜剥离的疗效和安全性
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-07-01 DOI: 10.5230/jgc.2023.23.e22
Eun Jeong Gong, Hyun Lim, Sang Jin Lee, Do Hoon Kim

Purpose: Endoscopic submucosal dissection (ESD) is an effective treatment for early gastrointestinal neoplasms. However, this is a time-consuming procedure requiring various devices. This study aimed to evaluate the efficacy and safety of the ClearCut™ Knife H-type, which is an integrated needle-tipped and insulated-tipped (IT) knife.

Materials and methods: Between July 2020 and September 2021, 99 patients with gastric epithelial neoplasms scheduled for ESD at three tertiary care hospitals were randomly assigned to H-knife (ClearCut™ Knife H-type) or IT-knife (conventional IT knife) groups. Procedure times, therapeutic outcomes, and adverse events were analyzed.

Results: A total of 98 patients (50 in the H-knife group and 48 in the IT-knife group) were analyzed. The median total procedure time was 11.9 minutes (range, 4.4-47.2 minutes) in the H-knife group and 12.7 minutes (range, 5.2-137.7 minutes) in the IT-knife group (P=0.209). Unlike the IT-knife group, which required additional devices in all cases, no additional devices were used in the H-knife group (P<0.001). En-bloc resection was performed for all lesions in both groups. The incidence of adverse events was not significantly different between groups (4.0% in the H-knife group vs. 8.3% in the IT-knife group; P=0.431).

Conclusions: The newly developed hybrid device, the ClearCut™ Knife H-type, had comparable efficacy to the conventional IT knife for gastric ESD.

Trial registration: Clinical Research Information Service Identifier: KCT0005164.

目的:内镜下粘膜下剥离术(ESD)是治疗早期胃肠道肿瘤的有效方法。然而,这是一个耗时的过程,需要各种设备。本研究旨在评估ClearCut™刀h型的有效性和安全性,这是一种集成的针尖和绝缘尖头(IT)刀。材料与方法:选取2020年7月至2021年9月在三家三级医院行ESD的胃上皮性肿瘤患者99例,随机分为H-knife (ClearCut™Knife h型)组和IT- Knife(传统IT刀)组。分析手术时间、治疗结果和不良事件。结果:共分析98例患者,其中h刀组50例,it刀组48例。h刀组的中位总手术时间为11.9分钟(范围4.4-47.2分钟),it刀组的中位总手术时间为12.7分钟(范围5.2-137.7分钟)(P=0.209)。与所有病例都需要额外装置的IT刀组不同,h刀组不需要额外装置(结论:新开发的混合装置ClearCut™Knife h型与传统IT刀治疗胃ESD的疗效相当。试验注册:临床研究信息服务标识:KCT0005164。
{"title":"Efficacy and Safety of ClearCut™ Knife H-type in Endoscopic Submucosal Dissection for Gastric Neoplasms: A Multicenter, Randomized Trial.","authors":"Eun Jeong Gong,&nbsp;Hyun Lim,&nbsp;Sang Jin Lee,&nbsp;Do Hoon Kim","doi":"10.5230/jgc.2023.23.e22","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e22","url":null,"abstract":"<p><strong>Purpose: </strong>Endoscopic submucosal dissection (ESD) is an effective treatment for early gastrointestinal neoplasms. However, this is a time-consuming procedure requiring various devices. This study aimed to evaluate the efficacy and safety of the ClearCut™ Knife H-type, which is an integrated needle-tipped and insulated-tipped (IT) knife.</p><p><strong>Materials and methods: </strong>Between July 2020 and September 2021, 99 patients with gastric epithelial neoplasms scheduled for ESD at three tertiary care hospitals were randomly assigned to H-knife (ClearCut™ Knife H-type) or IT-knife (conventional IT knife) groups. Procedure times, therapeutic outcomes, and adverse events were analyzed.</p><p><strong>Results: </strong>A total of 98 patients (50 in the H-knife group and 48 in the IT-knife group) were analyzed. The median total procedure time was 11.9 minutes (range, 4.4-47.2 minutes) in the H-knife group and 12.7 minutes (range, 5.2-137.7 minutes) in the IT-knife group (P=0.209). Unlike the IT-knife group, which required additional devices in all cases, no additional devices were used in the H-knife group (P<0.001). En-bloc resection was performed for all lesions in both groups. The incidence of adverse events was not significantly different between groups (4.0% in the H-knife group vs. 8.3% in the IT-knife group; P=0.431).</p><p><strong>Conclusions: </strong>The newly developed hybrid device, the ClearCut™ Knife H-type, had comparable efficacy to the conventional IT knife for gastric ESD.</p><p><strong>Trial registration: </strong>Clinical Research Information Service Identifier: KCT0005164.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 3","pages":"451-461"},"PeriodicalIF":2.5,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/86/ae/jgc-23-451.PMC10412977.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10032020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feasibility and Potential of Reduced Port Surgery for Total Gastrectomy With Overlap Esophagojejunal Anastomosis Method. 食管-空肠重叠吻合法全胃切除术小口手术的可行性与潜力。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-07-01 DOI: 10.5230/jgc.2023.23.e26
Ho Seok Seo, Sojung Kim, Kyo Young Song, Han Hong Lee

Purpose: Reduced port surgery (RPS) for gastric cancer has been frequently reported in distal gastrectomies but rarely in total gastrectomies. This study aimed to determine the feasibility of 3-port totally laparoscopic total gastrectomy (TLTG) with overlapping esophagojejunal (EJ) anastomosis.

Materials and methods: A total of 81 patients who underwent curative TLTG for gastric cancer (36 and 45 patients with 3-port and 5-port TLTG, respectively) were evaluated. All 3-port TLTG procedures were performed with the same method as 5-port TLTG, including EJ anastomosis with the intracorporeal overlap method using a linear stapler, except for the number of ports and assistants. Short-term outcomes, including the number of lymph nodes (LNs) harvested by station and postoperative complications, were analyzed retrospectively.

Results: Clinical characteristics were not significantly different among the groups, except that the 3-port TLTG group was younger and had a lower rate of pulmonary comorbidity. There were no cases of open conversion or additional port placement. All operative details and the number of harvested LNs did not differ between the groups, but the rate of suprapancreatic LN harvest was higher in the 3-port TLTG group. No significant differences were observed in the overall complication rates between the 2 groups.

Conclusions: Three-port TLTG with overlapping EJ anastomoses using a linear stapler is a feasible RPS procedure for total gastrectomy to treat gastric cancer.

目的:缩小胃口手术(RPS)治疗胃癌在远端胃切除术中屡见不鲜,但在全胃切除术中却很少报道。本研究旨在探讨食管空肠(EJ)重叠吻合的三孔腹腔镜全胃切除术(TLTG)的可行性。材料与方法:对81例胃癌行根治性tlg的患者(3孔tlg 36例,5孔tlg 45例)进行评价。所有3口TLTG手术均采用与5口TLTG相同的方法,包括使用线性吻合器与体内重叠法进行EJ吻合,除了端口和助手的数量不同。回顾性分析短期结果,包括手术切除淋巴结数量和术后并发症。结果:各组间临床特征无显著差异,但3端口TLTG组年龄更轻,肺部合并症发生率更低。没有病例开放转换或额外的端口放置。所有的手术细节和切除的LN数量在两组之间没有差异,但3端口TLTG组胰腺上LN的切除率更高。两组总并发症发生率无显著差异。结论:线性吻合器三口TLTG吻合术是全胃切除术治疗胃癌可行的RPS方法。
{"title":"Feasibility and Potential of Reduced Port Surgery for Total Gastrectomy With Overlap Esophagojejunal Anastomosis Method.","authors":"Ho Seok Seo,&nbsp;Sojung Kim,&nbsp;Kyo Young Song,&nbsp;Han Hong Lee","doi":"10.5230/jgc.2023.23.e26","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e26","url":null,"abstract":"<p><strong>Purpose: </strong>Reduced port surgery (RPS) for gastric cancer has been frequently reported in distal gastrectomies but rarely in total gastrectomies. This study aimed to determine the feasibility of 3-port totally laparoscopic total gastrectomy (TLTG) with overlapping esophagojejunal (EJ) anastomosis.</p><p><strong>Materials and methods: </strong>A total of 81 patients who underwent curative TLTG for gastric cancer (36 and 45 patients with 3-port and 5-port TLTG, respectively) were evaluated. All 3-port TLTG procedures were performed with the same method as 5-port TLTG, including EJ anastomosis with the intracorporeal overlap method using a linear stapler, except for the number of ports and assistants. Short-term outcomes, including the number of lymph nodes (LNs) harvested by station and postoperative complications, were analyzed retrospectively.</p><p><strong>Results: </strong>Clinical characteristics were not significantly different among the groups, except that the 3-port TLTG group was younger and had a lower rate of pulmonary comorbidity. There were no cases of open conversion or additional port placement. All operative details and the number of harvested LNs did not differ between the groups, but the rate of suprapancreatic LN harvest was higher in the 3-port TLTG group. No significant differences were observed in the overall complication rates between the 2 groups.</p><p><strong>Conclusions: </strong>Three-port TLTG with overlapping EJ anastomoses using a linear stapler is a feasible RPS procedure for total gastrectomy to treat gastric cancer.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 3","pages":"487-498"},"PeriodicalIF":2.5,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6e/75/jgc-23-487.PMC10412980.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10032019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial Intelligence in Surgery and Its Potential for Gastric Cancer. 手术中的人工智能及其在胃癌治疗中的潜力。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-07-01 DOI: 10.5230/jgc.2023.23.e27
Takahiro Kinoshita, Masaru Komatsu

Artificial intelligence (AI) has made significant progress in recent years, and many medical fields are attempting to introduce AI technology into clinical practice. Currently, much research is being conducted to evaluate that AI can be incorporated into surgical procedures to make them safer and more efficient, subsequently to obtain better outcomes for patients. In this paper, we review basic AI research regarding surgery and discuss the potential for implementing AI technology in gastric cancer surgery. At present, research and development is focused on AI technologies that assist the surgeon's understandings and judgment during surgery, such as anatomical navigation. AI systems are also being developed to recognize in which the surgical phase is ongoing. Such a surgical phase recognition systems is considered for effective storage of surgical videos and education, in the future, for use in systems to objectively evaluate the skill of surgeons. At this time, it is not considered practical to let AI make intraoperative decisions or move forceps automatically from an ethical standpoint, too. At present, AI research on surgery has various limitations, and it is desirable to develop practical systems that will truly benefit clinical practice in the future.

人工智能(AI)近年来取得了重大进展,许多医疗领域都在尝试将人工智能技术引入临床实践。目前,人们正在进行大量研究,以评估人工智能是否可以纳入外科手术,使其更安全、更有效,从而为患者带来更好的结果。在本文中,我们回顾了人工智能在手术方面的基础研究,并讨论了人工智能技术在胃癌手术中的应用潜力。目前,研发的重点是辅助外科医生在手术过程中的理解和判断的人工智能技术,如解剖导航。人工智能系统也正在开发中,以识别正在进行的手术阶段。这样的手术阶段识别系统被认为可以有效地存储手术视频和教育,在未来,用于客观评估外科医生技能的系统。此时,从伦理的角度来看,让人工智能做出术中决策或自动移动镊子也被认为是不切实际的。目前,人工智能在外科手术方面的研究存在各种局限性,希望能够开发出实用的系统,真正造福于未来的临床实践。
{"title":"Artificial Intelligence in Surgery and Its Potential for Gastric Cancer.","authors":"Takahiro Kinoshita,&nbsp;Masaru Komatsu","doi":"10.5230/jgc.2023.23.e27","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e27","url":null,"abstract":"<p><p>Artificial intelligence (AI) has made significant progress in recent years, and many medical fields are attempting to introduce AI technology into clinical practice. Currently, much research is being conducted to evaluate that AI can be incorporated into surgical procedures to make them safer and more efficient, subsequently to obtain better outcomes for patients. In this paper, we review basic AI research regarding surgery and discuss the potential for implementing AI technology in gastric cancer surgery. At present, research and development is focused on AI technologies that assist the surgeon's understandings and judgment during surgery, such as anatomical navigation. AI systems are also being developed to recognize in which the surgical phase is ongoing. Such a surgical phase recognition systems is considered for effective storage of surgical videos and education, in the future, for use in systems to objectively evaluate the skill of surgeons. At this time, it is not considered practical to let AI make intraoperative decisions or move forceps automatically from an ethical standpoint, too. At present, AI research on surgery has various limitations, and it is desirable to develop practical systems that will truly benefit clinical practice in the future.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 3","pages":"400-409"},"PeriodicalIF":2.5,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/03/1f/jgc-23-400.PMC10412972.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10330668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Outcomes of Gastrectomy for Gastric Cancer in Patients Aged >80 Years: A Systematic Literature Review and Meta-Analysis. 年龄>80岁的胃癌患者行胃切除术的预后:系统文献综述和meta分析
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-07-01 DOI: 10.5230/jgc.2023.23.e23
Zelalem Chimdesa Merga, Ji Sung Lee, Chung-Sik Gong

This meta-analysis examined the surgical management of older patients (>80 years) with gastric cancer, who were often excluded from randomized controlled trials. We analyzed 23 retrospective cohort studies involving 18,372 patients and found that older patients had a higher in-hospital mortality rate (relative risk [RR], 3.23; 95% confidence interval [CI], 1.46-7.17; P<0.01) and more post-operative complications (RR, 1.36; 95% CI, 1.19-1.56; P<0.01) than did younger patients. However, the surgical complications were similar between the two groups. Older patients were more likely to undergo less extensive lymph node dissection and longer hospital stays. Although older patients had statistically significant post-operative medical complications, they were not deprived of surgery for gastric cancer. The comorbidities and potential risks of post-operative complications should be carefully evaluated in older patients, highlighting the importance of careful patient selection. Overall, this meta-analysis provides recommendations for the surgical management of older patients with gastric cancer. Careful patient selection and evaluation of comorbidities should be performed to minimize the risk of post-operative complications in older patients, while recognizing that they should not be deprived of surgery for gastric cancer.

本荟萃分析研究了老年胃癌患者(>80岁)的手术治疗,这些患者通常被排除在随机对照试验之外。我们分析了23项回顾性队列研究,涉及18372例患者,发现老年患者的住院死亡率更高(相对危险度[RR], 3.23;95%置信区间[CI], 1.46-7.17;P
{"title":"Outcomes of Gastrectomy for Gastric Cancer in Patients Aged >80 Years: A Systematic Literature Review and Meta-Analysis.","authors":"Zelalem Chimdesa Merga,&nbsp;Ji Sung Lee,&nbsp;Chung-Sik Gong","doi":"10.5230/jgc.2023.23.e23","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e23","url":null,"abstract":"<p><p>This meta-analysis examined the surgical management of older patients (>80 years) with gastric cancer, who were often excluded from randomized controlled trials. We analyzed 23 retrospective cohort studies involving 18,372 patients and found that older patients had a higher in-hospital mortality rate (relative risk [RR], 3.23; 95% confidence interval [CI], 1.46-7.17; P<0.01) and more post-operative complications (RR, 1.36; 95% CI, 1.19-1.56; P<0.01) than did younger patients. However, the surgical complications were similar between the two groups. Older patients were more likely to undergo less extensive lymph node dissection and longer hospital stays. Although older patients had statistically significant post-operative medical complications, they were not deprived of surgery for gastric cancer. The comorbidities and potential risks of post-operative complications should be carefully evaluated in older patients, highlighting the importance of careful patient selection. Overall, this meta-analysis provides recommendations for the surgical management of older patients with gastric cancer. Careful patient selection and evaluation of comorbidities should be performed to minimize the risk of post-operative complications in older patients, while recognizing that they should not be deprived of surgery for gastric cancer.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 3","pages":"428-450"},"PeriodicalIF":2.5,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/b1/jgc-23-428.PMC10412976.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10032021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer. 预测程序性细胞死亡-1检查点抑制剂治疗晚期胃癌疗效的最佳肿瘤突变负荷截止值
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-07-01 DOI: 10.5230/jgc.2023.23.e29
Jae Yeon Jang, Youngkyung Jeon, Sun Young Jeong, Sung Hee Lim, Won Ki Kang, Jeeyun Lee, Seung Tae Kim

Purpose: The optimal tumor mutational burden (TMB) value for predicting treatment response to programmed cell death-1 (PD-1) checkpoint inhibitors in advanced gastric cancer (AGC) remains unclear. We aimed to investigate the optimal TMB cutoff value that could predict the efficacy of PD-1 checkpoint inhibitors in AGC.

Materials and methods: Patients with AGC who received pembrolizumab or nivolumab between October 1, 2020, and July 27, 2021, at Samsung Medical Center in Korea were retrospectively analyzed. The TMB levels were measured using a next-generation sequencing assay. Based on receiver operating characteristic curve analysis, the TMB cutoff value was determined.

Results: A total 53 patients were analyzed. The TMB cutoff value for predicting the overall response rate (ORR) to PD-1 checkpoint inhibitors was defined as 13.31 mutations per megabase (mt/Mb) with 56% sensitivity and 95% specificity. Based on this definition, 7 (13.2%) patients were TMB-high (TMB-H). The ORR differed between the TMB-low (TMB-L) and TMB-H (8.7% vs. 71.4%, P=0.001). The progression-free survival and overall survival (OS) for 53 patients were 1.93 (95% confidence interval [CI], 1.600-2.268) and 4.26 months (95% CI, 2.992-5.532). The median OS was longer in the TMB-H (20.8 months; 95% CI, 2.292-39.281) than in the TMB-L (3.31 months; 95% CI, 1.604-5.019; P=0.049).

Conclusions: The TMB cutoff value for predicting treatment response in AGC patients who received PD-1 checkpoint inhibitor monotherapy as salvage treatment was 13.31 mt/Mb. When applying the programmed death ligand-1 status to TMB-H, patients who would benefit from PD-1 checkpoint inhibitors can be selected.

目的:预测晚期胃癌(AGC)对程序性细胞死亡-1 (PD-1)检查点抑制剂治疗反应的最佳肿瘤突变负担(TMB)值尚不清楚。我们的目的是研究可以预测PD-1检查点抑制剂在AGC中的疗效的最佳TMB截止值。材料和方法:回顾性分析2020年10月1日至2021年7月27日在韩国三星医疗中心接受派姆单抗或纳武单抗治疗的AGC患者。使用新一代测序法测量TMB水平。根据接收机工作特性曲线分析,确定TMB截止值。结果:共分析53例患者。预测PD-1检查点抑制剂总缓解率(ORR)的TMB临界值定义为每兆酶13.31个突变(mt/Mb),敏感性56%,特异性95%。根据该定义,7例(13.2%)患者为tmb -高(TMB-H)。TMB-low (TMB-L)和TMB-H的ORR差异较大(8.7% vs. 71.4%, P=0.001)。53例患者的无进展生存期和总生存期(OS)分别为1.93个月(95%可信区间[CI], 1.600-2.268)和4.26个月(95% CI, 2.992-5.532)。TMB-H组的中位生存期更长(20.8个月;95% CI, 2.292-39.281)高于TMB-L组(3.31个月;95% ci, 1.604-5.019;P = 0.049)。结论:在接受PD-1检查点抑制剂单一治疗作为挽救治疗的AGC患者中,预测治疗反应的TMB临界值为13.31 mt/Mb。当将程序性死亡配体-1状态应用于TMB-H时,可以选择从PD-1检查点抑制剂中获益的患者。
{"title":"The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer.","authors":"Jae Yeon Jang,&nbsp;Youngkyung Jeon,&nbsp;Sun Young Jeong,&nbsp;Sung Hee Lim,&nbsp;Won Ki Kang,&nbsp;Jeeyun Lee,&nbsp;Seung Tae Kim","doi":"10.5230/jgc.2023.23.e29","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e29","url":null,"abstract":"<p><strong>Purpose: </strong>The optimal tumor mutational burden (TMB) value for predicting treatment response to programmed cell death-1 (PD-1) checkpoint inhibitors in advanced gastric cancer (AGC) remains unclear. We aimed to investigate the optimal TMB cutoff value that could predict the efficacy of PD-1 checkpoint inhibitors in AGC.</p><p><strong>Materials and methods: </strong>Patients with AGC who received pembrolizumab or nivolumab between October 1, 2020, and July 27, 2021, at Samsung Medical Center in Korea were retrospectively analyzed. The TMB levels were measured using a next-generation sequencing assay. Based on receiver operating characteristic curve analysis, the TMB cutoff value was determined.</p><p><strong>Results: </strong>A total 53 patients were analyzed. The TMB cutoff value for predicting the overall response rate (ORR) to PD-1 checkpoint inhibitors was defined as 13.31 mutations per megabase (mt/Mb) with 56% sensitivity and 95% specificity. Based on this definition, 7 (13.2%) patients were TMB-high (TMB-H). The ORR differed between the TMB-low (TMB-L) and TMB-H (8.7% vs. 71.4%, P=0.001). The progression-free survival and overall survival (OS) for 53 patients were 1.93 (95% confidence interval [CI], 1.600-2.268) and 4.26 months (95% CI, 2.992-5.532). The median OS was longer in the TMB-H (20.8 months; 95% CI, 2.292-39.281) than in the TMB-L (3.31 months; 95% CI, 1.604-5.019; P=0.049).</p><p><strong>Conclusions: </strong>The TMB cutoff value for predicting treatment response in AGC patients who received PD-1 checkpoint inhibitor monotherapy as salvage treatment was 13.31 mt/Mb. When applying the programmed death ligand-1 status to TMB-H, patients who would benefit from PD-1 checkpoint inhibitors can be selected.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 3","pages":"476-486"},"PeriodicalIF":2.5,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/58/54/jgc-23-476.PMC10412974.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9978398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Artificial Intelligence in Gastric Cancer: Surgical and Therapeutic Perspectives: A Comprehensive Review. 人工智能在胃癌中的作用:手术和治疗角度:综合综述。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-07-01 DOI: 10.5230/jgc.2023.23.e31
JunHo Lee, Hanna Lee, Jun-Won Chung

Stomach cancer has a high annual mortality rate worldwide necessitating early detection and accurate treatment. Even experienced specialists can make erroneous judgments based on several factors. Artificial intelligence (AI) technologies are being developed rapidly to assist in this field. Here, we aimed to determine how AI technology is used in gastric cancer diagnosis and analyze how it helps patients and surgeons. Early detection and correct treatment of early gastric cancer (EGC) can greatly increase survival rates. To determine this, it is important to accurately determine the diagnosis and depth of the lesion and the presence or absence of metastasis to the lymph nodes, and suggest an appropriate treatment method. The deep learning algorithm, which has learned gastric lesion endoscopyimages, morphological characteristics, and patient clinical information, detects gastric lesions with high accuracy, sensitivity, and specificity, and predicts morphological characteristics. Through this, AI assists the judgment of specialists to help select the correct treatment method among endoscopic procedures and radical resections and helps to predict the resection margins of lesions. Additionally, AI technology has increased the diagnostic rate of both relatively inexperienced and skilled endoscopic diagnosticians. However, there were limitations in the data used for learning, such as the amount of quantitatively insufficient data, retrospective study design, single-center design, and cases of non-various lesions. Nevertheless, this assisted endoscopic diagnosis technology that incorporates deep learning technology is sufficiently practical and future-oriented and can play an important role in suggesting accurate treatment plans to surgeons for resection of lesions in the treatment of EGC.

胃癌在世界范围内的年死亡率很高,需要早期发现和准确治疗。即使是经验丰富的专家也会根据几个因素做出错误的判断。人工智能(AI)技术正在迅速发展,以协助这一领域。在这里,我们旨在确定人工智能技术如何用于胃癌诊断,并分析它如何帮助患者和外科医生。早期胃癌(EGC)的早期发现和正确治疗可大大提高生存率。为了确定这一点,重要的是准确确定病变的诊断和深度以及是否存在淋巴结转移,并建议适当的治疗方法。深度学习算法学习了胃病变内镜图像、形态特征和患者临床信息,检测胃病变具有较高的准确性、敏感性和特异性,并预测形态特征。通过此,AI辅助专家判断,帮助在内镜手术和根治性手术中选择正确的治疗方法,并帮助预测病变的切除边缘。此外,人工智能技术提高了相对缺乏经验和熟练的内镜诊断医师的诊断率。然而,用于学习的数据存在局限性,例如定量数据量不足,回顾性研究设计,单中心设计以及非各种病变的病例。然而,这种结合深度学习技术的辅助内镜诊断技术具有足够的实用性和前瞻性,可以在EGC治疗中为外科医生提供准确的治疗方案,切除病变方面发挥重要作用。
{"title":"The Role of Artificial Intelligence in Gastric Cancer: Surgical and Therapeutic Perspectives: A Comprehensive Review.","authors":"JunHo Lee,&nbsp;Hanna Lee,&nbsp;Jun-Won Chung","doi":"10.5230/jgc.2023.23.e31","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e31","url":null,"abstract":"<p><p>Stomach cancer has a high annual mortality rate worldwide necessitating early detection and accurate treatment. Even experienced specialists can make erroneous judgments based on several factors. Artificial intelligence (AI) technologies are being developed rapidly to assist in this field. Here, we aimed to determine how AI technology is used in gastric cancer diagnosis and analyze how it helps patients and surgeons. Early detection and correct treatment of early gastric cancer (EGC) can greatly increase survival rates. To determine this, it is important to accurately determine the diagnosis and depth of the lesion and the presence or absence of metastasis to the lymph nodes, and suggest an appropriate treatment method. The deep learning algorithm, which has learned gastric lesion endoscopyimages, morphological characteristics, and patient clinical information, detects gastric lesions with high accuracy, sensitivity, and specificity, and predicts morphological characteristics. Through this, AI assists the judgment of specialists to help select the correct treatment method among endoscopic procedures and radical resections and helps to predict the resection margins of lesions. Additionally, AI technology has increased the diagnostic rate of both relatively inexperienced and skilled endoscopic diagnosticians. However, there were limitations in the data used for learning, such as the amount of quantitatively insufficient data, retrospective study design, single-center design, and cases of non-various lesions. Nevertheless, this assisted endoscopic diagnosis technology that incorporates deep learning technology is sufficiently practical and future-oriented and can play an important role in suggesting accurate treatment plans to surgeons for resection of lesions in the treatment of EGC.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 3","pages":"375-387"},"PeriodicalIF":2.5,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/06/9c/jgc-23-375.PMC10412973.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10032016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial Intelligence in Gastric Cancer Imaging With Emphasis on Diagnostic Imaging and Body Morphometry. 人工智能在胃癌影像学中的应用,重点是诊断成像和身体形态计量学。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-07-01 DOI: 10.5230/jgc.2023.23.e30
Kyung Won Kim, Jimi Huh, Bushra Urooj, Jeongjin Lee, Jinseok Lee, In-Seob Lee, Hyesun Park, Seongwon Na, Yousun Ko

Gastric cancer remains a significant global health concern, coercing the need for advancements in imaging techniques for ensuring accurate diagnosis and effective treatment planning. Artificial intelligence (AI) has emerged as a potent tool for gastric-cancer imaging, particularly for diagnostic imaging and body morphometry. This review article offers a comprehensive overview of the recent developments and applications of AI in gastric cancer imaging. We investigated the role of AI imaging in gastric cancer diagnosis and staging, showcasing its potential to enhance the accuracy and efficiency of these crucial aspects of patient management. Additionally, we explored the application of AI body morphometry specifically for assessing the clinical impact of gastrectomy. This aspect of AI utilization holds significant promise for understanding postoperative changes and optimizing patient outcomes. Furthermore, we examine the current state of AI techniques for the prognosis of patients with gastric cancer. These prognostic models leverage AI algorithms to predict long-term survival outcomes and assist clinicians in making informed treatment decisions. However, the implementation of AI techniques for gastric cancer imaging has several limitations. As AI continues to evolve, we hope to witness the translation of cutting-edge technologies into routine clinical practice, ultimately improving patient care and outcomes in the fight against gastric cancer.

胃癌仍然是一个重要的全球健康问题,迫使需要在成像技术的进步,以确保准确的诊断和有效的治疗计划。人工智能(AI)已经成为胃癌成像的有力工具,特别是在诊断成像和身体形态测量方面。本文就人工智能在胃癌影像学中的最新进展及应用进行综述。我们研究了人工智能成像在胃癌诊断和分期中的作用,展示了其在提高患者管理这些关键方面的准确性和效率方面的潜力。此外,我们还探讨了人工智能身体形态测量技术在评估胃切除术临床影响方面的应用。人工智能在这方面的应用对理解术后变化和优化患者预后具有重要意义。此外,我们研究了人工智能技术对胃癌患者预后的现状。这些预后模型利用人工智能算法来预测长期生存结果,并帮助临床医生做出明智的治疗决策。然而,人工智能技术在胃癌成像中的应用存在一些局限性。随着人工智能的不断发展,我们希望看到尖端技术转化为常规临床实践,最终改善患者对胃癌的护理和治疗效果。
{"title":"Artificial Intelligence in Gastric Cancer Imaging With Emphasis on Diagnostic Imaging and Body Morphometry.","authors":"Kyung Won Kim,&nbsp;Jimi Huh,&nbsp;Bushra Urooj,&nbsp;Jeongjin Lee,&nbsp;Jinseok Lee,&nbsp;In-Seob Lee,&nbsp;Hyesun Park,&nbsp;Seongwon Na,&nbsp;Yousun Ko","doi":"10.5230/jgc.2023.23.e30","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e30","url":null,"abstract":"<p><p>Gastric cancer remains a significant global health concern, coercing the need for advancements in imaging techniques for ensuring accurate diagnosis and effective treatment planning. Artificial intelligence (AI) has emerged as a potent tool for gastric-cancer imaging, particularly for diagnostic imaging and body morphometry. This review article offers a comprehensive overview of the recent developments and applications of AI in gastric cancer imaging. We investigated the role of AI imaging in gastric cancer diagnosis and staging, showcasing its potential to enhance the accuracy and efficiency of these crucial aspects of patient management. Additionally, we explored the application of AI body morphometry specifically for assessing the clinical impact of gastrectomy. This aspect of AI utilization holds significant promise for understanding postoperative changes and optimizing patient outcomes. Furthermore, we examine the current state of AI techniques for the prognosis of patients with gastric cancer. These prognostic models leverage AI algorithms to predict long-term survival outcomes and assist clinicians in making informed treatment decisions. However, the implementation of AI techniques for gastric cancer imaging has several limitations. As AI continues to evolve, we hope to witness the translation of cutting-edge technologies into routine clinical practice, ultimately improving patient care and outcomes in the fight against gastric cancer.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 3","pages":"388-399"},"PeriodicalIF":2.5,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/b8/jgc-23-388.PMC10412978.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9978395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Gastric Cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1